<DOC>
	<DOCNO>NCT00378599</DOCNO>
	<brief_summary>This exploratory study Phase 3 , single-arm , multi-center , open-label study pegylated interferon alfa-2b , PEG-IFN alpha-2b ( PEG-Intron ) ribavirin ( RBV ) determine sustain virologic response ( SVR ) 24-week follow-up 48 week subject orthotopic liver transplantation ( OLT ) chronic hepatitis C ( HCV ) recurrence .</brief_summary>
	<brief_title>Effects Pegylated Interferon Alfa-2b Ribavirin After Orthotopic Liver Transplantation Subjects With Chronic Hepatitis C Recurrence ( P04590AM3 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Subjects must confirm prior medication washout time observe . Subject must 18 70 year age either gender race . Subject must transplant endstage hepatitis C fulminant hepatitis C. Subject must document : persistent HCV viremia OLT define plasma positive HCV RNA quantitative reverse transcriptionpolymerase chain reaction ( RTPCR ) , A liver transplant perform least 3 month prior screen 3 year prior screen . Subject must stable dos immunosuppression least 1 month . Compensated liver disease minimum hematologic , biochemical , serologic criterion ( Day 1 ) baseline visit . Alphafetoprotein value ( AFP ) less equal 250ng/mL . If AFP great 100 ng/mL , patient need evidence normal liver ( magnetic resonance imaging ) MRI normal chest computerize tomography ( CT ) scan within last 3 month screen period . For subject history diabetes hypertension , clearance ophthalmologist obtain prior treatment start ( Day 1/Visit 2 ) . Subjects history mild depression may consider entry study . Female subject pregnant breastfeeding must either postmenopausal , surgically sterile use 2 method birth control . Sexually active male subject practice acceptable , method contraception . Contraceptive measure review female subject visit . Dual method contraception must use 1 month prior start treatment 6 month treatment discontinuation . Pregnancy test obtain Screen Visit Day 1 Visit prior initiation treatment must negative . Pregnant woman , woman plan become pregnant , male subject whose partner want become pregnant , breastfeed woman ( study 6 month study completion ) . Subject used investigational product within 30 day prior Screening participate clinical study . Prior treatment chronic hepatitis C postliver transplant , include limited antiviral immunomodulatory product , interferon product , RBV , either monotherapy combination . Subjects organ transplant . Any subject receive positive hepatitis C core antibody ( HBcAb ) HCV positive donor liver graft . Retransplantation liver rejection graft failure . Evidence decompensated liver disease . Known coagulopathies include hemophilia . Known hemoglobinopathy . Known glucose6phosphate dehydrogenase ( G6PD ) deficiency . Hypersensitivity alpha interferon and/or RBV . Coinfection hepatitis B virus ( HBV ) and/or human immunodeficiency virus ( HIV ) . Evidence active suspect malignancy history malignancy within last 5 year ( exception pretransplant hepatocellular carcinoma histologically within Milan criterion , adequately treat basal squamous cell carcinoma skin ) . Any known preexisting medical condition could interfere subject 's participation completion study . Subject substance abuser . Subjects treat buprenorphine ( Subutex ) stable 6 month may include . Patients weigh 135 kg ; Is participate clinical study ( y ) ; Is allergic sensitivity study drug excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>